Evidence map›Paper›PMID 38613685›Full record

SynthesisPsychopharmacology2024

Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy.

Steven J Nieto, Han Du, Lindsay R Meredith, Suzanna Donato, Molly Magill, Lara A Ray

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Steven J NietoDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. snieto@psych.ucla.edu.ORCID http://orcid.org/0000-0003-1158-5211
Han DuDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Lindsay R MeredithDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Suzanna DonatoDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Molly MagillCenter for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island, USA.
Lara A RayDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.

Funding

Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
Integrating findings across stages of medication development for AUDR21AA029771 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2021 to 2022
$438k
Applying behavioral economics to screen medications for alcohol use disorderF32AA029288 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NIETO, STEVEN J · 2021 to 2022
$115k
Neuroimmune Treatment for AUD: Testing Moderators of Clinical Response and Mechanisms of ActionF31AA029295 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MEREDITH BROUSSARD, LINDSAY · 2022 to 2023
$59k
NIAAA NIH HHS F31 AA029295NIAAA NIH HHS F31AA029295NIAAA NIH HHS F32 AA029288NIAAA NIH HHS F32AA029288NIAAA NIH HHS K24 AA025704NIAAA NIH HHS K24AA025704NIAAA NIH HHS R21 AA029771NIAAA NIH HHS R21AA029771
6 · The paper itself

Abstract

rationaleThe alcohol cue exposure paradigm is a common method for evaluating new treatments for alcohol use disorder (AUD); however, it is unclear if medication-related reductions in cue-induced craving in the human laboratory can predict the clinical success of those medications in reducing alcohol consumption during clinical trials.

objectivesTo use a novel meta-analytic approach to test whether medication effect sizes on cue-induced alcohol craving are associated with clinical efficacy in clinical trials.

methodWe searched the literature for medications tested for AUD treatment using both the alcohol cue-reactivity paradigm and randomized clinical trials (RCTs). For alcohol cue-reactivity studies, we computed medication effect sizes for cue-induced alcohol craving (k = 36 studies, 15 medications). For RCTs, we calculated medication effect sizes for heavy drinking and abstinence (k = 139 studies, 19 medications). Using medication as the unit of analysis, we applied the Williamson-York bivariate weighted least squares estimation to account for errors in both independent and dependent variables. We also conducted leave-one-out cross validation simulations to examine the predictive utility of cue-craving medication effect sizes on RCT heavy drinking and abstinence endpoints.

resultsThere was no significant relationship between medication effects on cue-induced alcohol craving in the human laboratory and medication effects on heavy drinking (

conclusionsThe preliminary results of the current study challenge the assumption that alcohol cue-reactivity alone can be used as an early efficacy indicator for AUD pharmacotherapy development. These findings suggest that a wider range of early efficacy indicators and experimental paradigms be considered for Phase II testing of novel compounds.

Indexed as

AlcoholismCravingCuesRandomized Controlled Trials as TopicAlcohol DrinkingHumansTreatment OutcomeAlcohol cue-reactivityAlcohol use disorderCue-induced cravingHuman laboratoryMedication developmentRandomized clinical trials

Identifiers

PMID38613685
PMCPMC11269462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.